Health TrialsbyHealthPanel

Prognostic Model of Hypertension

ConditionHypertension
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorXinjiang Medical University

About this trial

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

Disqualifiers

Patients with secondary hypertension, patients with liver and kidney dysfunction,

patients with mental disorders, and patients who are unwilling to participate in this trial

Trial population

A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Standard therapy

    Other intervention

    Individualized blood pressure reduction program

Treatment groups

50,000 Participants
are divided into 1 treatment group
Group A: 21 intervention

Trial outcomes

Primary outcomes

1

Resistant hypertension

Time frame
10 years of follow-up Resistant hypertension occurred during this period
2

Death (all-cause mortality, mortality from hypertension complications)

Time frame
10 years of follow-up deaths occurred during this period

Secondary outcomes

1

Major adverse cardiovascular events

Time frame
10 years of follow-up deaths occurred during this period

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xinjiang Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now